Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression
Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.
How this was made

The 30-second read
Why it matters
The trade hinges on a mixed read-through: primary and key secondary efficacy endpoints appear strong versus placebo, but the company disclosed three treatment-related SAEs, including depression cases and a suicide attempt by a non-responder, which triggered a sharp selloff.
Market read
Strong efficacy data was not enough to offset newly disclosed serious safety events, driving a large same-day decline and increasing the probability of heightened safety-focused scrutiny.
What to watch
The article does not specify SAE rates, adjudication details, or whether the suicide attempt was causally linked; investors may over-discount without full safety context, and upcoming EMBRACE topline in Q4 2027 is a longer-dated catalyst.
Background
Helus is running a Phase 3 program (PARADIGM) for deuterated psilocin analog HLP003 in major depressive disorder, with FDA Breakthrough Therapy Designation for adjunctive MDD.
Market effects
Adds to the ongoing debate on psychedelic therapy safety, potentially increasing scrutiny and volatility across the psychedelic depression development cohort.
US biotech sentiment may soften for similar clinical-stage psychedelic names as safety signals dominate near-term trading.
Could influence international investor appetite for deuterated psilocin and related psychedelic programs, especially around FDA review expectations.
Counterpoint
The efficacy delta is large and fast-acting, and the SAEs may be rare and not necessarily predictive of broader tolerability if causality is clarified.
Key entities
- companyHelus Pharma
Reported Phase 3 APPROACH results for HLP003 in MDD and disclosed three treatment-related serious adverse events.
- drug_programHLP-003 (HLP003)
Deuterated psilocin therapy candidate evaluated in the Phase 3 APPROACH trial for major depressive disorder.
- clinical_trialAPPROACH
Late-stage Phase 3 trial in moderate-to-severe major depressive disorder; results included efficacy endpoints and SAE disclosures.




